Abstract
Pediatric lipidology evolved from investigations conducted by outstanding lipidologists and clinicians. This chapter reviews the many historical milestones that have led to the current understanding of lipidology. Abnormal lipid metabolism is associated with an increased risk of cardiovascular and cerebrovascular disease, which are leading causes of disability and death worldwide.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mahmood SS, et al. The Framingham heart study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. 2014;383(9921):999–1008.
Enos WF, Holmes RH, Beyer J. Coronary disease among United States soldiers killed in action in Korea; preliminary report. J Am Med Assoc. 1953;152(12):1090–3.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.
Berenson GS, Bogalusa Heart Study Investigators. Bogalusa heart study: a long-term community study of a rural biracial (black/white) population. Am J Med Sci. 2001;322(5):293–300.
Gidding SS, et al. Effects of secular trends in obesity on coronary risk factors in children: the Bogalusa heart study. J Pediatr. 1995;127(6):868–74.
Berenson GS, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa heart study. N Engl J Med. 1998;338(23):1650–6.
McGill HC Jr, et al. Association of Coronary Heart Disease Risk Factors with microscopic qualities of coronary atherosclerosis in youth. Circulation. 2000;102(4):374–9.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486–97.
Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128(Suppl 5):S213.
De Ferranti SD, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association. Circulation. 2019;139(13):e603–34.
McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr. 2003;143(1):74–80.
Food and Drug Administration. Drugs@ FDA: FDA approved drug products. 2016.
Rosenson RS. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther. 2003;1(4):495–505.
Riaz H, et al. Meta-analysis of placebo-controlled randomized controlled trials on the prevalence of statin intolerance. Am J Cardiol. 2017;120(5):774–81.
Luirink IK, et al. 20-year follow-up of statins in children with familial hypercholesterolemia. N Engl J Med. 2019;381:1547.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Correya, T., Valaiyapathi, B., Ashraf, A. (2023). History and Significance of Pediatric Lipidology. In: Ashraf, A., Sunil, B. (eds) Pediatric Dyslipidemia. Springer, Cham. https://doi.org/10.1007/978-3-031-24113-0_1
Download citation
DOI: https://doi.org/10.1007/978-3-031-24113-0_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-24112-3
Online ISBN: 978-3-031-24113-0
eBook Packages: MedicineMedicine (R0)